Key result
Concurrent diagnosis of metabolic syndrome in patients undergoing coronary stenting for STEMI was associated with a lower risk of in-hospital mortality.
Why the study?
Studies on the impact of metabolic syndrome on treatment outcomes in STEMI patients are limited, prompting an evaluation of in-hospital mortality among those undergoing coronary stenting.
Does concurrent metabolic syndrome affect in-hospital mortality in STEMI patients undergoing coronary stenting?
Observational (n=11,634)
Yes
Does concurrent metabolic syndrome affect in-hospital mortality in STEMI patients undergoing coronary stenting?
Concurrent diagnosis of metabolic syndrome in STEMI patients undergoing coronary stenting is paradoxically associated with decreased in-hospital mortality.
Answers are grounded in this paper and cite their sources.
MetS signals higher in-hospital mortality risk during STEMI stenting; provides first RCT data to guide risk stratification and trials.
Background Metabolic syndrome (MetS) has been recognized as a global health problem. Concurrent MetS diagnosis in patients with ST-elevation myocardial infarction (STEMI) is becoming increasingly common. Given the paucity of studies on the impact of MetS on treatment outcomes in STEMI patients, the purpose of this study was to evaluate in-hospital mortality in STEMI patients with a concurrent MetS diagnosis undergoing a stenting procedure to treat their underlying coronary artery disease. Method Patients with or without MetS who underwent coronary stenting following STEMI between 2005 and 2014 were identified from the National Inpatient Sample database. Patients' demographics, comorbidities, and outcomes were compared using a t-test and Pearson's Chi-square test. In addition, 1:1 propensity score matching was performed for age, gender, and race. Results Out of 1,938,097 STEMI patients, 5,817 patients with MetS underwent coronary stenting following STEMI and were matched with 5,817 patients with no Mets. MetS group had significantly higher rates of diabetes, hypertension, hyperlipidemia, chronic kidney disease, and obstructive sleep apnea than the no MetS group but lower rates of heart failure and chronic obstructive pulmonary disease. In-hospital mortality following STEMI was significantly lower in patients with MetS (2.5% vs. 7.1%, p<0.001) and remained significant after adjusting for potential confounders (odds ratio (OR) 0.34, 95% confidence interval (95% CI) 0.28-0.42, p<0.0001). Conclusion Concurrent diagnosis of MetS among patients undergoing coronary stenting is associated with a decreased in-hospital mortality risk. The impact of specific MetS components on the observed reduction in mortality remains unclear and warrants evaluation in future studies.
No takes yet. Share an insight, caveat, or question.
Igbinosa et al. (2022) conducted an observational in ST-elevation myocardial infarction (STEMI) (n=11,634). Metabolic syndrome vs. No metabolic syndrome was evaluated on In-hospital mortality (OR 0.34, 95% CI 0.28-0.42, p=<0.0001). Concurrent diagnosis of metabolic syndrome in patients undergoing coronary stenting for STEMI was associated with a lower risk of in-hospital mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: